Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates

Saleh, Jasmine; Subtil, Antonio; Hristov, Alexandra C.

doi:10.1016/j.humpath.2023.06.001

Cited by 3 publications

(3 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It contains large cells with pleomorphic, immunoblastic or anaplastic morphology (Figure 2). The CD30 antigen can be found in at least 75% of neoplastic cells [19,29]. The condition accounts for 9% of all CTCLs.…”

Section: Primary Cutaneous Anaplastic Large Cell Lymphomamentioning

confidence: 99%

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Stein,

Robak,

Biernat

et al. 2024

JCM

View full text Add to dashboard Cite

One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Recently, significant progress has been made in understanding the genetics and treatment of these disorders. This review article summarises the clinical evidence supporting the current treatment options for these diseases. Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date.

show abstract

Section: Primary Cutaneous Anaplastic Large Cell Lymphomamentioning

confidence: 99%

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Stein,

Robak,

Biernat

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…The identification of these characteristics in epidermal lymphocytes, as opposed to dermal lymphocytes, provides support for the diagnosis of eMF. Among the pan T-cell markers, CD7 is most commonly lost in MF, followed by CD5 and CD2 [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…Despite the utilization of immunophenotyping and T-cell clonality studies, a definitive diagnosis of MF may remain elusive, necessitating vigilant clinical follow-up with repeat skin biopsies [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Decoding Early Mycosis Fungoides: Histopathologic and Immunohistochemical Clues

Kaya Terzi

2024

Cureus

View full text Add to dashboard Cite

Introduction: Primary cutaneous lymphomas, notably mycosis fungoides (MF), present diagnostic challenges in recognizing early mycosis fungoides (eMF) due to their diverse clinical and histopathologic manifestations. The aim of our study was to use adjunctive histopathologic and immunohistochemical methods in eMF cases to make an early diagnosis and to facilitate differentiation from other dermatoses. Methods: This retrospective study analyzed 35 cases of eMF diagnosed at a single center. Demographic and clinicopathologic data were collected, and histopathologic features were assessed. Comparative analyses were conducted with conditions mimicking eMF, including large plaque parapsoriasis (LPP), psoriasis, and chronic dermatitis. Immunohistochemistry for T-cell markers (CD3, CD4, CD8, CD2, CD7) was performed. Results: With the scoring we applied in our study, a sensitivity of 91.43% (95% CI; 76.94% to 98.20%) and specificity of 85.71% (95% CI; 69.74% to 95.19%) for distinguishing eMF from LPP. Epidermotropism emerged as a crucial histopathologic marker, with a notable absence in most cases of cutaneous dermatitis (81.6% and 80% for CD and psoriasis, respectively) (P < 0.001). Immunohistochemistry revealed a T-helper phenotype (CD4+/CD8-) in the majority of eMF cases (78.1%), while CD4+/CD8+ and CD8+/CD4- patterns were less common (28.5% and 8.5%, respectively). Conclusion: This study underscores the complexities in distinguishing eMF from inflammatory skin diseases, advocating for a comprehensive diagnostic approach.

show abstract

Emerging concepts in dermatopathology: a special issue of neoplastic, inflammatory, and special-site dermatopathology and important practice considerations

Lehman

Erickson

2023

Human Pathology

View full text Add to dashboard Cite

Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates

Cited by 3 publications

References 182 publications

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin

Decoding Early Mycosis Fungoides: Histopathologic and Immunohistochemical Clues

Emerging concepts in dermatopathology: a special issue of neoplastic, inflammatory, and special-site dermatopathology and important practice considerations

Contact Info

Product

Resources

About